TuHURA Q1 cash $6.3M; secures $50M credit facility; IFx-2.0 gets ODD in melanoma

TuHURA Biosciences, Inc./NV

Cash and equivalents $6.3M at March 31, 2026; net operating cash outflow $4.4M in Q1.
Established $50M credit facility with largest stockholder at 12% interest, maturing 2031; extends runway into 2028.
R&D expenses $5.2M (up from $4.6M YoY); G&A $2.3M (up from $2.0M YoY).
FDA Orphan Drug Designation granted for IFx-2.0 in stage IIB-IV melanoma.
Appointed Craig Tendler as CMO and Amanda Garofalo as SVP Clinical Operations.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.